Validation of Progranulin as a Biomarker for Sepsis
- Conditions
- Sepsis
- Registration Number
- NCT03280576
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Brief Summary
Progranulin blood concentrations in patients with sepsis will be analysed in relation to disease status in order to validate progranulin as a biomarker for sepsis. Patients undergoing cardiac surgery will serve as controls.
- Detailed Description
Single nucleotide polymorphisms with known effects on Progranulin plasma concentrations will be assessed in a separate analysis. Expression levels of microRNAs isolated from plasma, circulating exosomes and blood cells will be determined by next-generation sequencing to characterize epigenetic influences on progranulin plasma levels.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 556
- Sepsis or Septic Shock defined according to SEPSIS-3 criteria - Age > 18 years
- No informed consent
- Age < 18 years
- Pregnancy
- Immunosuppression (including transplantation)
- Charlson Comorbidity Index > 0 (healthy volunteers)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in progranulin plasma concentrations during ICU - therapy ICU admission, day 1, day 4 of ICU therapy Blood samples will be taken at the abovementioned time points
- Secondary Outcome Measures
Name Time Method Change in miRNA expression levels in exosomes, serum and blood cells during ICU - therapy ICU admission, day 1, day 4 of ICU therapy Blood samples will be taken at the abovementioned time points
Trial Locations
- Locations (2)
Department of Anesthesiology, Klinikum Neuperlach
🇩🇪Munich, Bavaria, Germany
Department of Anesthesiology, LMU Munich
🇩🇪Munich, Bavaria, Germany